Beazley's QuIRP program is unique in the medical malpractice market. Instead of working from industry-wide quality benchmarks (which frequently conflict with one another), Beazley adopts a tailored approach to the circumstances and needs of each individual client. At the beginning of the policy period, Beazley agrees with the client on a set of target quality improvements. If these targets are met by the end of the policy period, the client will receive a pre-agreed return premium, which may be a substantial sum.

Under the QuIRP program, a client can receive a payment even if it has made a claim during the policy period. No quality measures can guarantee impunity from lawsuits, but through the QuIRP program Beazley seeks to institutionalize procedures that, over time, should reduce claims.

Since the inception of the QuIRP program, Beazley has returned over $10,000,000 in premium due to quality improvements put in place by the insureds. 

Healthcare providers participating in Beazley’s Quality Indicator Return Premium (QuIRP) program can now choose to incorporate an artificial intelligence-powered early warning system for labor and delivery into their risk management program.

The technology, developed by North Carolina-based AI developer PeriGen, aims to significantly reduce unanticipated adverse events.

PeriGen’s PeriWatch Vigilance system works alongside existing electronic fetal monitors and assesses long-term trends in fetal heart rate, contractions, maternal vitals and labor progress to provide bedside clinicians with a steady, real-time flow of risk management information.  PeriWatch Vigilance also provides telemedicine tools allowing a single patient safety clinician to provide ‘safety net’ monitoring across an entire network of hospitals.

Beazley’s Quality Indicator Return Premium (QuIRP) program helps clients to improve their risk management procedures and patient outcomes by setting target quality improvements. Clients that are eligible for QuIRP can apply to have Perigen adoption qualify for part of their potential QuIRP premium return, thereby helping to fund an investment in the technology.

For further information, please contact Matt McCullaugh.

Beazley recognises that the benefits of engaging patients in taking an active role in their care include increased patient safety and risk mitigation.

Enhanced informed patient consent through Emmi Solutions offers a range of online programmes designed to improve and record patient understanding of their recommended medical procedures. Healthcare organizations nationwide use Emmi's web-based education programs to engage patients and positively impact the patient experience across the continuum of care. Informed patient consent is a critical risk management precaution, and Emmi's programmes help ensure that consent is secured.

Hospitals that utilize Emmi Solutions' interactive healthcare education programs could be entitled to receive a portion of the premium paid for their medical malpractice insurance back at the end of the policy period.Information about Emmi Solutions is available here: http://www.emmisolutions.com/.

Beazley promotes the innovative monitoring of hospital patients to provide early warning of clinical crises through OBS Medical's Visensia® technology.

Recognised by Frost and Sullivan as a 2008 North American Technology Innovation award winner, OBS Medical's Visensia monitoring technology provides early warning of clinical crises. Visensia fuses data from multiple vital signs into a numerical index of a patient's wellness. When the predictive index reaches or surpasses a set threshold, an alert is triggered, indicating a patient may be at greater risk of deterioration.

Beazley has acknowledged that this type of technology may be beneficial in promoting better patient outcomes. Hospitals implementing Visensia in a manner approved by Beazley's underwriters will be entitled to receive reimbursement of a portion of the premium paid for their medical malpractice insurance back at the end of the policy period.The story behind OBS is a fascinating one - its technology is an adaptation of techniques originally used to monitor jet engines in aircraft - and can be read here: http://www.oxford-biosignals.com/.Detailed information about how Visensia works can be read here: http://www.obsmedical.com/.